Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to ...

TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist ...

Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the ...

The study1 by Emma Guttman-Yassky and colleagues represents an important and innovative contribution to the evolving treatment landscape of moderate-to-severe atopic dermatitis, particularly by ...

Severe atopic dermatitis increases risk for sleep and memory disturbances, according to results of a cross-sectional study.

In this episode, the panel discusses the next wave of biologic development in atopic dermatitis, including bispecific ...

Site-specific involvement and history of conventional therapy use were associated with MDA at 52 weeks in patients with AD with early response.

When confronted with chronic eczematous dermatitis, clinicians should try to differentiate between intrinsic (atopic dermatitis [AD]) and extrinsic (allergic or irritant contact dermatitis) causes. AD ...

What is contact dermatitis? Contact dermatitis is a reaction that occurs when something touches your skin and triggers a rash. The rash may appear right away or it could take some time to develop.

The Phase 2b study of EVO756 in adults with atopic dermatitis is designed to test how well this new oral drug works and how safe it is. The official title shows it is a randomized, double blind, ...

Geeta Yadav, MD, comments on new guidance for using advanced topical nonsteroidal therapies for chronic hand eczema.

Dermatitis can cause redness, itching, dryness, cracking and irritation, and is recognised as one of the most common occupational skin conditions ...